Reference
Peptide Regulatory Status Tracker
The status of 59 peptides under three rule sets: US FDA drug approval, FDA's section 503A compounding categories, and the 2026 WADA Prohibited List. As of Nov 10, 2026, 10 are in FDA-approved drugs, 21 are prohibited by name or class on the WADA List, and six (BPC-157, Epitalon, KPV, MOTS-c, Semax, TB-500) are covered by a draft HHS compounding policy without being FDA-approved.
Checked against each source on Nov 10, 2026
What changed in 2026
Apr 22, 2026
FDA removed a group of peptides from 503A Category 2 after their nominations were withdrawn, including BPC-157, TB-500, CJC-1295, KPV, MOTS-c, Semax, Selank and Epitalon. GHK-Cu was also taken out of Category 1. [3][6]
May 14, 2026
FDA's updated category list places GHK-Cu, for routes other than injection, back in Category 1. Injectable GHK-Cu remains a withdrawn nomination. [2]
Jul 24, 2026
FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax to the 503A bulks list, and voted against emideltide (DSIP). The votes are advisory. [5]
Oct 30, 2026
HHS published a draft enforcement discretion policy covering 503A compounding with those six peptides while FDA decides, through rulemaking, whether to add them to the 503A bulks list. [4]
Status by compound
Select a compound to open its guide. The legend below the table explains each status.
| Compound | FDA approval (US) | 503A compounding (US) | WADA 2026 |
|---|---|---|---|
| ACE-031 | Not FDA-approved | Not in a category | Prohibited · S4.3 Named as a decoy activin receptor. |
| Adipotide | Not FDA-approved | Not in a category | Not named · S0 rule |
| Albiglutide | Approved, discontinued Tanzeum, approved 2014. | Not applicable | Not named · S0 rule Discontinued worldwide; S0 covers discontinued drugs. |
| Amycretin | Not FDA-approved | Not in a category | Not named · S0 rule |
| AOD-9604 | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Prohibited · S2.2.3 Named as a growth hormone fragment. |
| Argireline | Not FDA-approved Cosmetic ingredient. | Not in a category | Not on the List |
| BPC-157 | Not FDA-approved | HHS enforcement discretion Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026. | Prohibited · S0 Named in S0. |
| Bremelanotide | FDA-approved Vyleesi, 2019. | Not applicable | Not on the List |
| Cagrilintide | Not FDA-approved | Not in a category | Not named · S0 rule |
| Cerebrolysin | Not FDA-approved Approved in some other countries. | Not in a category | Not on the List |
| CJC-1295 | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Prohibited · S2.2.4 Named as a GHRH analogue. |
| Dapiglutide | Not FDA-approved | Not in a category | Not named · S0 rule |
| Dihexa | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Not named · S0 rule |
| DSIP (emideltide) | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn; PCAC voted against adding it to the 503A bulks list in July 2026. | Not named · S0 rule |
| Dulaglutide | FDA-approved Trulicity, 2014. | Not applicable | Not on the List |
| Ecnoglutide | Not FDA-approved | Not in a category | Not named · S0 rule |
| Elamipretide | FDA-approved Forzinity, 2025 (accelerated approval). | Not applicable | Not on the List |
| Epitalon | Not FDA-approved | HHS enforcement discretion Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026. | Not named · S0 rule |
| Exenatide | FDA-approved Byetta, 2005; Bydureon. | Not applicable | Not on the List |
| Follistatin-344 | Not FDA-approved | Not in a category | Prohibited · S4.3 Follistatin is named as a myostatin-binding protein. |
| GHK-Cu | Not FDA-approved Cosmetic ingredient. | Category 1 Category 1 for routes other than injection (May 14, 2026). The injectable nomination was withdrawn from Category 2. | Not on the List |
| GHRP-2 | Not FDA-approved | Category 3 503A Category 3; 503B Category 2 for injectable and nasal routes. | Prohibited · S2.2.4 Named as a GH-releasing peptide. |
| GHRP-6 | Not FDA-approved | Category 3 503A Category 3; 503B Category 2. | Prohibited · S2.2.4 Named as a GH-releasing peptide. |
| Glutathione | Not FDA-approved Not approved as a stand-alone drug; an ingredient of BSS Plus irrigation solution. | Category 1 | Not on the List |
| Gonadorelin | Approved, discontinued Factrel, approved 1982. | Not applicable | Prohibited · S2.2.1 Named; prohibited in males. |
| Hexarelin | Not FDA-approved | Not in a category | Prohibited · S2.2.4 Named as examorelin (hexarelin). |
| Humanin | Not FDA-approved | Not in a category | Not named · S0 rule |
| IGF-1 DES | Not FDA-approved | Not in a category | Prohibited · S2.3 IGF-1 analogues are named. |
| IGF-1 LR3 | Not FDA-approved | Not in a category | Prohibited · S2.3 IGF-1 analogues are named. |
| Ipamorelin | Not FDA-approved | Nomination withdrawn 503A nomination withdrawn from Category 2; 503B Category 2. | Prohibited · S2.2.4 Named as a growth hormone secretagogue. |
| Kisspeptin-10 | Not FDA-approved | Category 2 | Prohibited · S2.2.1 Kisspeptin and its analogues are named; prohibited in males. |
| KPV | Not FDA-approved | HHS enforcement discretion Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026. | Not named · S0 rule |
| Liraglutide | FDA-approved Victoza, 2010; Saxenda, 2014. | Not applicable | Not on the List |
| Lixisenatide | FDA-approved Adlyxin, 2016; also in Soliqua 100/33. | Not applicable | Not on the List |
| LL-37 | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Not named · S0 rule |
| Matrixyl | Not FDA-approved Cosmetic ingredient. | Not in a category | Not on the List |
| Mazdutide | Not FDA-approved Approved in China. | Not in a category | Not on the List |
| Melanotan II | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Not named · S0 rule |
| MGF | Not FDA-approved | Category 3 | Prohibited · S2.3 Mechano growth factors are named. |
| Mod GRF 1-29 | Not FDA-approved | Not in a category | Prohibited · S2.2.4 Within GHRH and its analogues. |
| MOTS-c | Not FDA-approved | HHS enforcement discretion Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026. | Prohibited · S4.4.1 Named as an AMPK activator. |
| NAD+ | Not FDA-approved | Category 1 | Not on the List |
| Oxytocin | FDA-approved Pitocin and generic oxytocin injection. | Not applicable | Not on the List |
| P21 | Not FDA-approved | Not in a category | Not named · S0 rule |
| PEG-MGF | Not FDA-approved | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Prohibited · S2.3 Mechano growth factors are named. |
| Pemvidutide | Not FDA-approved | Not in a category | Not named · S0 rule |
| PNC-27 | Not FDA-approved | Not in a category | Not named · S0 rule |
| Retatrutide | Not FDA-approved | Not in a category | Not named · S0 rule |
| Selank | Not FDA-approved Approved in Russia. | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Not on the List |
| Semaglutide | FDA-approved Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021. | Not applicable | Not on the List |
| Semax | Not FDA-approved Approved in Russia. | HHS enforcement discretion Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026. | Not on the List |
| Sermorelin | Approved, discontinued Geref, approved 1990. | Not applicable | Prohibited · S2.2.4 Named as a GHRH analogue. |
| Survodutide | Not FDA-approved | Not in a category | Not named · S0 rule |
| TB-500 | Not FDA-approved | HHS enforcement discretion Draft HHS policy, Oct 30, 2026; PCAC recommended adding it to the 503A bulks list in July 2026. | Prohibited · S2.3 Named as a thymosin-β4 derivative. |
| Tesamorelin | FDA-approved Egrifta, 2010. | Not applicable | Prohibited · S2.2.4 Named as a GHRH analogue. |
| Thymalfasin (thymosin α1) | Not FDA-approved Approved in other countries. | Nomination withdrawn Removed from Category 2 after the nomination was withdrawn. | Not on the List |
| Thymosin beta-4 | Not FDA-approved | Not in a category | Prohibited · S2.3 Thymosin-β4 is named. |
| Tirzepatide | FDA-approved Mounjaro, 2022; Zepbound, 2023. | Not applicable | Not on the List |
| VIP | Not FDA-approved | Category 1 | Not on the List |
What each status means
FDA approval
- FDA-approved
- Drugs@FDA lists an approved application for a product containing the compound.
- Approved, discontinued
- FDA approved a product, but every product containing the compound has since been discontinued in the US.
- Not FDA-approved
- Drugs@FDA lists no approved product containing the compound.
503A compounding
- HHS enforcement discretion
- Covered by the October 30, 2026 draft HHS policy: HHS does not intend to take enforcement action against licensed pharmacies and physicians compounding it under section 503A while FDA rulemaking proceeds.
- Category 1
- Nominated and under evaluation; FDA has not identified significant safety risks.
- Category 2
- FDA has identified significant safety risks.
- Category 3
- Nominated without adequate supporting information.
- Nomination withdrawn
- Formerly in Category 2; the nomination was withdrawn, so the substance is no longer in any category.
- Not applicable
- An FDA-approved drug. The nomination categories cover bulk substances that are not components of approved drugs.
- Not in a category
- Not in any of FDA's 503A nomination categories.
WADA Prohibited List
- Prohibited
- Named on the List, or within a class the List names, at the section shown.
- Not named · S0 rule
- Not named, but WADA's S0 class prohibits any substance with no current approval by a health authority anywhere for human therapeutic use, including drugs in development.
- Not on the List
- Not named on the List. S0 does not reach a substance approved as a medicine somewhere; for cosmetic and supplement ingredients, an anti-doping organization can confirm status.
How to read this table
The three columns answer different questions. FDA approval says whether a finished drug product containing the compound has been approved. The 503A column covers whether state-licensed pharmacies may use the compound as a bulk ingredient in compounding, which is a separate process from approval. The WADA column applies only to athletes subject to the World Anti-Doping Code.
A status in one column says nothing about the others. A peptide can be covered by the HHS compounding policy, not FDA-approved, and prohibited by WADA at the same time, as BPC-157 is.
Frequently asked questions
Is BPC-157 FDA-approved?
No. No product containing BPC-157 is FDA-approved. FDA removed it from 503A Category 2 in April 2026, and a draft HHS policy published on October 30, 2026 says HHS does not intend to take enforcement action against licensed pharmacies and physicians compounding it under section 503A while FDA rulemaking proceeds. WADA names it as prohibited under S0.
Which peptides does the October 2026 HHS compounding policy cover?
Six: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. They are the six that FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend for the 503A bulks list. The policy is a draft statement of enforcement discretion. It does not add them to the bulks list or make them FDA-approved drugs.
What do FDA's 503A Category 1, 2 and 3 mean?
They sort bulk drug substances nominated for compounding that have no USP monograph and are not components of FDA-approved drugs. Category 1 is under evaluation with no significant safety risks identified. Category 2 has significant safety risks identified. Category 3 was nominated without adequate supporting information.
Is retatrutide FDA-approved?
No. As of November 10, 2026, Drugs@FDA lists no approved product containing retatrutide, and it is not in any 503A category. WADA's S0 class covers substances with no current approval by any health authority, which includes drugs still in clinical development.
Which peptides are on the WADA Prohibited List?
The 2026 List names BPC-157 (S0); CJC-1295, sermorelin, tesamorelin, ipamorelin, GHRP-2, GHRP-6 and hexarelin (S2.2.4); AOD-9604 (S2.2.3); TB-500, thymosin-β4, mechano growth factors and IGF-1 analogues (S2.3); kisspeptin and gonadorelin, in males (S2.2.1); follistatin and ACE-031 (S4.3); and MOTS-c (S4.4.1). GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the List.
Sources
- Drugs@FDA approval records (openFDA drugsfda dataset). US FDA. Queried November 10, 2026.
- 503A Categories: Bulk Drug Substances Nominated for Use in Compounding. US FDA. Updated May 14, 2026.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US FDA. Content current as of April 22, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (FR Doc. 2026-22192). US HHS, Federal Register. Published October 30, 2026.
- FDA PCAC recommends six peptides for the 503A bulks list. Buchanan Ingersoll & Rooney. July 2026.
- FDA announces removal of 12 peptides from Category 2 and schedules PCAC meetings. Orrick. April 2026.
- World Anti-Doping Code International Standard: Prohibited List 2026. World Anti-Doping Agency. In force January 1 to December 31, 2026.
This page summarizes public regulatory documents for reference. It is not legal advice, and statuses change: check the linked source before relying on any entry. WADA's 2027 Prohibited List takes effect on January 1, 2027. For research and educational purposes only.
Last checked Nov 10, 2026